| abstract |
The present invention relates to a compound of the general formula (I) [wherein Ar 1 is phenyl or a 5- or 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from N, S or O Where the N-heteroatom in the heteroaryl group can be oxidized to N + -(O − ), R 1 is lower alkyl, halogen, cyano, or cycloalkyl; Ar 2 is a 5- or 6-membered heteroaryl group containing 1, 2, 3, or 4 heteroatoms selected from N, S, or O, wherein N-hetero in the heteroaryl group The atom can be oxidized to N + -(O − ) or is benzo [b] thiophenyl and R 2 is lower alkyl substituted with hydrogen, lower alkyl, halogen, cyano, hydroxyl The halogene Lower alkyl substituted with amino, lower alkyl substituted with amino, lower alkyl substituted with alkoxy, lower alkyl substituted with amide, or cycloalkyl, and X is CH or N, n is 1 or 2, m is 1 or 2, and a pharmaceutically acceptable salt, racemic mixture thereof, Or the corresponding enantiomer and / or its optical isomer and / or its stereoisomer. This compound is a CNS disease, substance abuse, alcohol and drug addiction, obsessive compulsive disorder, cognitive impairment, bipolar disorder, mood disorder, major depression, treatment resistance associated with positive (psychotic) and negative symptoms of schizophrenia Depression, anxiety disorder, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disorder, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, muscle atrophy It can be used for the treatment of lateral sclerosis, epilepsy, arthritis effects, autoimmune diseases, viral and fungal infections, cardiovascular diseases, ophthalmic and inflammatory retinal diseases, and balance disorders. |